A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 412 participants.
Also called NCT03985293
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 412 participants
- Sponsor
- Registry
-
NCT03985293 -
2019-000218-12
-
- Other papers using this trial's data
- Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Hungary, Poland, Slovakia, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03985293. Randomized; quadruple masking; primary purpose treatment. Start 2019-10-15 (actual); primary completion 2021-06-08 (actual). Results posted on 2022-06-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- PF-06882961
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct03985293- Content hash
6192885beb9ff197beda1891542a79bc22a94fcf05eb0527313d33780b0fb4b8